Alcami Corp - Company Profile

Powered by

All the sales intelligence you need on Alcami Corp in one solution.

  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Alcami Corp fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Alcami Corp.

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Alcami Corp Catalyst Calendar

Proactively evaluate Alcami Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

A sample of Alcami Corp Catalyst Calendar data

Event Date Event Type Company Name Ticker Symbol Drug Name Therapy Area Indication Source Type
Showing 3 of 6 results.
18 Jun 2027 GDCTWXYZ Lorem Lorem Lorem WXYZ Planned Lorem
31 Dec 2023 Phase II Trial Results Alcami Corp; LianBio; QED Therapeutics Inc LIAN infigratinib phosphate Oncology Adenocarcinoma Of The Gastroesophageal Junction; Bile Duct Cancer (Cholangiocarcinoma) ; Gastric Cancer; Solid Tumor Company Press Release
30 Dec 2022 Phase II Trial Completion Alcami Corp; LianBio; QED Therapeutics Inc LIAN infigratinib phosphate Oncology Adenocarcinoma Of The Gastroesophageal Junction; Bile Duct Cancer (Cholangiocarcinoma) ; Gastric Cancer; Solid Tumor Clinical Trial Registry
01 Jul 2022 Phase III Trial Initiation Alcami Corp; Bristol-Myers Squibb Co; Celgene Corp; Sarah Cannon Research Institute LLC BMY iberdomide hydrochloride Oncology Multiple Myeloma (Kahler Disease); Refractory Multiple Myeloma; Relapsed Multiple Myeloma Clinical Trial Registry
Catalyst Calendar

Feature

Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.

Benefit

Access:

  • Trial Events for trials conducted globally by a company, university, institute or CRO:  Trial Initiation, Trial Completion, Trial Results
  • Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
  • Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)

Value

Proactively evaluate companies and catalyst impacts

Stay ahead of the competition & improve corporate planning

Bolster business development with timely opportunities

Premium databases is part of our industry range of products

Gain a 360-degree view of Alcami Corp and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer